SCHEMBL20004086

SCHEMBL20004086

Fc1ccc(N2CCN(c3ccccn3)CC2)c(F)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.59
BCHE P06276 3/20 0.58
ACHE P22303 3/20 0.58
BACE1 P56817 3/20 0.58
KDM4E B2RXH2 2/20 0.53
LMNA P02545 2/20 0.53
HTR1A P08908 6/20 0.52
DRD4 P21917 6/20 0.52
DRD3 P35462 6/20 0.52
DRD2 P14416 5/20 0.52
HTR2A P28223 5/20 0.52
HTR7 P34969 5/20 0.52
SLC6A4 P31645 2/20 0.52
ADRA2C P18825 3/20 0.51
ADRA2A P08913 1/20 0.51
ADRA2B P18089 1/20 0.51
OPRK1 P41145 1/20 0.51
DRD1 P21728 2/20 0.50
DRD5 P21918 2/20 0.50
HRH1 P35367 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1127534 0.85 LMNA (0.62) POLBKDM4ELMNAHTR1ADRD4
SCHEMBL3075280 0.82 KDM4E (0.48) POLBKDM4ELMNAPLD1
SCHEMBL1126830 0.80 ALDH1A1 (0.59) POLBBCHEACHEBACE1KDM4E
SCHEMBL3076670 0.80 MAPT (0.53) POLBKDM4ELMNAHTR1ADRD4
SCHEMBL15800694 0.78 PLD1 (0.73) POLBKDM4EPLD1
SCHEMBL21353591 0.78
SCHEMBL29857922 0.78 PLD1 (0.73) POLBKDM4EPLD1
SCHEMBL22653986 0.77 ME2 (0.51) KDM4ELMNADPP4DPP9
SCHEMBL19998596 0.77 DRD2 (0.52) KDM4EHTR1ADRD4DRD3DRD2
SCHEMBL3878479 0.75 BCHE (0.57) POLBBCHEACHEBACE1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3943490-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2022-01-26 EP disclosed
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-20 US disclosed
EP-3277677-B9 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LTD (GB) 2021-07-14 EP disclosed
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-06 US disclosed
EP-3842427-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2021-06-30 EP disclosed
EP-3277677-B1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LTD (GB) 2021-02-24 EP disclosed
US-10689345-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2020-06-23 US disclosed
US-20200181086-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2020-06-11 US disclosed
US-20190322624-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-10-24 US disclosed
US-20190284138-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-09-19 US disclosed
US-20190270708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-09-05 US disclosed
US-10343992-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors Missions Therapeutics Limited (GB) 2019-07-09 US disclosed
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2018-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 POLB 951/4885BCHE 1948/4885ACHE 2505/4885
US-10343992-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 POLB 809/4885BCHE 1995/4885ACHE 2715/4885
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 POLB 809/4885BCHE 1995/4885ACHE 2715/4885
US-20200181086-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 POLB 796/4885BCHE 1913/4885ACHE 2616/4885
US-20190284138-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 POLB 951/4885BCHE 1948/4885ACHE 2505/4885
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 POLB 809/4885BCHE 1995/4885ACHE 2715/4885
US-20190322624-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 POLB 809/4885BCHE 1995/4885ACHE 2715/4885
US-10689345-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 POLB 809/4885BCHE 1995/4885ACHE 2715/4885
US-20190270708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 POLB 809/4885BCHE 1995/4885ACHE 2715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.